InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-27 | 2026-02-27 | Elghandour Rami | Director & SEE REMARKS | Sale | 89.9K | $113.92 | $10.24M | 276.1K | View ↗ | |
| 2026-02-25 | 2026-02-25 | Gilson Michelle | CHIEF FINANCIAL OFFICER | Sale | 11.2K | $113.82 | $1.28M | 33.9K | View ↗ | |
| 2026-02-19 | 2026-02-19 | Gilson Michelle | CHIEF FINANCIAL OFFICER | Sale | 8,384 | $68.29 | $573K | 45.2K | View ↗ | |
| 2026-02-17 | 2026-02-18 | Gilson Michelle | CHIEF FINANCIAL OFFICER | Sale | 11.3K | $69.51 | $785K | 53.5K | View ↗ |
No annual data found.
Here’s Why Roivant Sciences Ltd (ROIV) Rallied in Q1
Gilead’s HIV Priority Review And Arcellx Deal Refocus Long‑Term Story
Gilead Sciences Annual Meeting: Directors, Pay Win Big; Pipeline Launches and Acquisitions Highlighted
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel